drug_type
RELEVANT_DRUG
intervention_type
Biologic (bispecific T-cell engager antibody)
drug_description
Intravenous bispecific T-cell engager antibody that binds DLL3 on tumor cells and CD3 on T cells to redirect and activate T cells to kill DLL3-positive cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Obrixtamig (BI 764532) is an intravenous bispecific T‑cell engager antibody that binds DLL3 on tumor cells and CD3 on T cells, physically bringing them together to form an immune synapse and activate T cells to release cytotoxic mediators and kill DLL3‑positive cells.
drug_name
BI 764532 (obrixtamig)
nct_id_drug_ref
NCT05916313